The inclusion of BAG3 in the gene panel testing for myofibrillar and inclusion body myopathies could improve the diagnosis yield of this condition and have already been implemented in France by the neuromuscular rare disease network, FILNEMUS, which has standardized national clinical practices (Krahn et al., 2019). Here, BAG3 is linked to glycogen storage disease VI.